Vaxon Biotech Overview
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Vaxon Biotech General Information
Description
Developer of therapeutic vaccines designed to offer treatment for cancer. The company's vaccines are developed to treat lung, gastric, prostate, breast, renal, liver and colorectal cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells, enabling patients to get treated from cancer and enjoy a healthy life.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Therapeutic Devices
Primary Office
- Tour CIT, BP 191
- 3 rue de l'Arrivée
- 75749 Paris
- France
+33 01 00 00 00 00
Vaxon Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Jan-2020 | Completed | Out of Business | |||
| 3. Early Stage VC | 01-Jan-2011 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Apr-2004 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 01-Jan-2003 | Completed | Startup |
Vaxon Biotech Patents
Vaxon Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3061559-A1 | Use of a vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient | Pending | 09-May-2017 | 000000000 | |
| EP-3634461-A1 | Use of a vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient | Pending | 09-May-2017 | 000000000 | |
| EP-3400954-A1 | Vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient | Inactive | 09-May-2017 | 000000000 | 0 |
| JP-2020520349-A | Use of a vaccine targeting a potential tert epitope to treat lung cancer in hla-a*0201 positive no smoking habit or former light smoking | Pending | 09-May-2017 | 000000000 | 0 |
| US-20200079819-A1 | Use of a vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient | Pending | 09-May-2017 | A61K38/08 |
Vaxon Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
